Unknown

Dataset Information

0

Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.

ABSTRACT: Clinical validation of S1P receptor modulation therapy was achieved with the approval of fingolimod (Gilenya, 1) as the first oral therapy for relapsing remitting multiple sclerosis. However, 1 causes a dose-dependent reduction in the heart rate (bradycardia), which occurs within hours after first dose. We disclose the identification of clinical compound BMS-986104 (3d), a novel S1P1 receptor modulator, which demonstrates ligand-biased signaling and differentiates from 1 in terms of cardiovascular and pulmonary safety based on preclinical pharmacology while showing equivalent efficacy in a T-cell transfer colitis model.

SUBMITTER: Dhar TG 

PROVIDER: S-EPMC4789672 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Clinical validation of S1P receptor modulation therapy was achieved with the approval of fingolimod (Gilenya, 1) as the first oral therapy for relapsing remitting multiple sclerosis. However, 1 causes a dose-dependent reduction in the heart rate (bradycardia), which occurs within hours after first dose. We disclose the identification of clinical compound BMS-986104 (3d), a novel S1P1 receptor modulator, which demonstrates ligand-biased signaling and differentiates from 1 in terms of cardiovascul  ...[more]

Similar Datasets

Unknown Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481.
| S-EPMC6421538 | biostudies-literature
Unknown Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5.
| S-EPMC4789665 | biostudies-literature
Unknown Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes.
| S-EPMC3811978 | biostudies-literature
Unknown Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
| S-EPMC5825103 | biostudies-literature
Unknown Pharmacology in translation: the preclinical and early clinical profile of the novel ?2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.
| S-EPMC5786456 | biostudies-literature
Unknown Robust Translation of ?-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects.
| S-EPMC4931879 | biostudies-other
Unknown Attenuation of murine sclerodermatous models by the selective S1P1 receptor modulator cenerimod.
| S-EPMC6345830 | biostudies-other
Unknown Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis.
| S-EPMC6761374 | biostudies-literature
Unknown Identification of potent tricyclic prodrug S1P1 receptor modulators.
| S-EPMC6071880 | biostudies-other
Unknown Benzofuran Derivatives as Potent, Orally Active S1P1 Receptor Agonists: A Preclinical Lead Molecule for MS.
| S-EPMC4017978 | biostudies-literature